RS51698B - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents

Pyrrolopyrimidines as protein kinase inhibitors

Info

Publication number
RS51698B
RS51698B YU99203A YUP99203A RS51698B RS 51698 B RS51698 B RS 51698B YU 99203 A YU99203 A YU 99203A YU P99203 A YUP99203 A YU P99203A RS 51698 B RS51698 B RS 51698B
Authority
RS
Serbia
Prior art keywords
ny1y2
ny3y4
heteroaryl
aryl
cycloalkyl
Prior art date
Application number
YU99203A
Other languages
Serbian (sr)
Inventor
Shelley Amendola
Chris Edlin
Paul Joseph Cox
Tahir Nadeem Majid
Stephanie Daniele Deprets
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Lain Mcfarlane Mclay
Davis John Aldous
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Priority to MEP-193/08A priority Critical patent/MEP19308A/en
Publication of RS99203A publication Critical patent/RS99203A/en
Publication of RS51698B publication Critical patent/RS51698B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Jedinjenje formulegdeR1 predstavlja vodonik, -C(=O)-NY1Y2, -C(=O)-OR5, -SO2-NY1Y2, -SO2-R7, -C(=O)R7, iliR1 predstavlja alkenil, alkeniloksi, alkil, alkynil, aril, heteroaril, heterocikloalkil, cikloalkil ili cikloalkilalkil, svaki po izboru supstituisan jednom ili više grupa odabranih od aril, cikloalkil, cijano, halo, heteroaril, heterocikloalkil, -CHO, -C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4,-N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -OR7, -C(=O)-R7, hidroksi, alkoksi i karboksi;R2 predstavalja jednu ili više grupa odabranih od vodonika, acil, alkilenedioksi, alkenil, alkeniloksi, alkinil, aril, cijano, halo, hidroksi, heteroaril, heterocikloalkil, nitro,R4, -C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7, N(R6)-C(=O)-NY3Y4, -N(R6)-C(=O)-OR7, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -SO2-NY1Y2 i -ZR4;R3 predstavlja H, cijano, halo, hidroksi, nitro, R4, NY1Y2, -ZR4, -C(=O)-OR5, C(=O)-R7, -C(=O)-NY1Y2, -N(R8)-C(=O)-R4, -N(R8)-C(=O)NY1Y2; -N(R8)-C(=O)-OR5, -SO2-NY3Y4 ili -N(R8)-SO2-R7, iliR3 predstavlja aril, heteroaril, alkenil ili alkinil, svaki po izboru supstituisan jednom ili više grupa odabranih od aril, cijano, halo, hidroksi, heteroaril, heterocikloalkil, nitro,-C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4,-N(R6)-C(=O)-OR7, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -SO2-NY1Y2 i -ZR4;R4 predstavlja alkil, cikloalkil ili cikloalklalkil svaki po izboru supstituisan jednom ili više grupa odabranih od aril, cikloalkil, cijano, halo, heteroaril, heterocikloalkil, hidroksi, -CHO, -C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7,-N(R6)-C(=O)-NY3Y4,-N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -OR7 i -C(=O)-R7pri čemu je u R4 je po izboru umetnuta grupa odabranaod O, S(O)n, i NR6R5 predstavlja vodonik, alkil, alkenil, aril, arilalkil, heteroaril ili heteroarilalkil;R6 predstavlja vodonik ili niži alkil;R7 predstavlja alkil, aril, arilalkil, cikloalkil, cikoalkilalkil, heteroaril, heteroarilalkil, heterocikloalkil ili heterocikloalkilalkil;R8 predstavlja vodonik ili niži alkil;Y1 i Y2 su nezavisno vodonik, alkenil, aril, cikloalkil, heteroaril ili alkil po izboru supstituisan jednom ili više grupa odabranih od aril, halo, heteroaril, hidroksi, -C(=O)-NY3Y4, -C(=O)-OR5, -NY3Y4, -N(R6)-C(=O)- R7, -N(R6)-C(=O)-NY3Y4, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4 i -OR7; or the grupa – NY1Y2 može da formira ciklični amin;Y3 i Y4 su nezavinso vodonik, alkenil, alkil, aril, arilalkil, cikloalkil, heteroaril ili heteroarilalkil; ili -NY3Y4 grupa može da formira ciklični amin;Z predstavlja O ili S(O)n; n je nula ili broj 1 ili 2; iliN-oksid, bioizoster kiseline, farmaceutski prihvatljiva so ili solvat datog jedinjenja; ili N-oksid, ili kiseli bioizostar date soli ili solvata,pri čemu alkenil je alifatična ugljovodonična grupa koja sadrži ugljenik-ugljenik dvostruku vezu i prav ili razgranat lanac sa 2 do 15 atoma ugljenika,pri čemThe compound of the formula R1 represents hydrogen, -C (= O) -NY1Y2, -C (= O) -OR5, -SO2-NY1Y2, -SO2-R7, -C (= O) R7, or R1 represents alkenyl, alkenyloxy, alkyl, alkynyl , aryl, heteroaryl, heterocycloalkyl, cycloalkyl or cycloalkylalkyl, each optionally substituted by one or more groups selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO, -C (= O) -NY1Y2, -C (= O ) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -SO2-R7, -N (R6) -SO2-NY3Y4, -OR7, -C (= O) -R7, hydroxy, alkoxy and carboxy; R2 represents one or more groups selected from hydrogen, acyl, alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy , heteroaryl, heterocycloalkyl, nitro, R4, -C (= O) -NY1Y2, -C (= O) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, N (R6) -C (= O) -NY3Y4, -N (R6) -C (= O) -OR7, -N (R6) -SO2-R7, -N (R6) -SO2-NY3Y4, -SO2-NY1Y2 and -ZR4; R3 represents H, cyano, halo, hydroxy, nitro, R4, NY1Y2, -ZR4, -C (= O) -OR5, C (= O) -R7, -C (= O) -NY1Y2, -N (R8) - C (= O) -R4, -N (R8) -C (= O) NY1Y2; -N (R8) -C (= O) -OR5, -SO2-NY3Y4 or -N (R8) -SO2-R7, or R3 represents aryl, heteroaryl, alkenyl or alkynyl, each optionally substituted by one or more groups selected from aryl , cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, -C (= O) -NY1Y2, -C (= O) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -C (= O) -OR7, -N (R6) -SO2-R7, -N (R6) -SO2-NY3Y4, -SO2-NY1Y2 and -ZR4; R4 represents alkyl, cycloalkyl or cycloalkylalkyl each optionally substituted by one or more groups selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, hydroxy, -CHO, -C (= O) -NY1Y2, -C ( = O) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -SO2-R7, -N ( R6) -SO2-NY3Y4, -OR7 and -C (= O) -R7 wherein R4 is an optionally inserted group selected from O, S (O) n, and NR6R5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R6 represents hydrogen or lower alkyl; R7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 represents hydrogen or lower alkyl; Y1 and Y2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, hydroxy, -C (= O) - NY3Y4, -C (= O) -OR5, -NY3Y4, -N (R6) -C (= O) - R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -SO2- R7, -N (R6) -SO2-NY3Y4 and -OR7; or the group - NY1Y2 may form a cyclic amine; Y3 and Y4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or a -NY3Y4 group may form a cyclic amine; Z represents O or S (O) n; n is zero or number 1 or 2; or N-oxide, an acid bioisoster, a pharmaceutically acceptable salt or solvate of a given compound; or N-oxide, or an acidic bioisomer of a given salt or solvate, wherein the alkenyl is an aliphatic hydrocarbon group containing a carbon-carbon double bond and a straight or branched chain of 2 to 15 carbon atoms, wherein

YU99203A 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors RS51698B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-193/08A MEP19308A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28
PCT/GB2002/002835 WO2003000695A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
RS99203A RS99203A (en) 2006-12-15
RS51698B true RS51698B (en) 2011-10-31

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
YU99203A RS51698B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
NZ537752A (en) 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
BRPI0416909A (en) * 2003-11-25 2007-01-16 Pfizer Prod Inc atherosclerosis treatment method
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
US7576053B2 (en) 2005-06-13 2009-08-18 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DK2343299T3 (en) 2005-12-13 2016-01-18 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
EA200970361A1 (en) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед KINASE INHIBITORS
ES2575797T3 (en) 2007-06-13 2016-07-01 Incyte Holdings Corporation Salts of the kinase inhibitor Janus (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanonitrile
US8349847B2 (en) 2008-01-11 2013-01-08 Durga Prasad Konakanchi Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents
PE20110223A1 (en) 2008-06-10 2011-05-07 Abbvie Inc DERIVATIVES OF PIRROLO [2,3-e] [1,2,4] TRIAZOLO [4,3-a] PIRAZIN, AS KINASE INHIBITORS
DK2432472T3 (en) 2009-05-22 2019-11-18 Incyte Holdings Corp 3- [4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL) -1H-PYRAZOL-1-YL] OCTAN OR HEPTAN NITRIL AS JAK INHIBITORS
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
PE20121336A1 (en) 2009-12-01 2012-11-03 Abbvie Inc NEW TRICYCLIC COMPOUNDS
MX364636B (en) 2010-03-10 2019-05-03 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors.
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN102093364B (en) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
KR20140040819A (en) 2011-06-20 2014-04-03 인사이트 코포레이션 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN104470919B (en) 2012-07-26 2016-07-06 葛兰素集团有限公司 2-(azaindole-2-base) benzimidazole as PAD4 inhibitor
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
MX2015012432A (en) 2013-03-13 2016-02-05 Abbvie Inc Pyridine cdk9 kinase inhibitors.
BR112015023013A2 (en) 2013-03-13 2017-07-18 Abbvie Inc cdk9 kinase inhibitors
TW201444836A (en) 2013-03-14 2014-12-01 Abbvie Inc Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
AU2014244194A1 (en) * 2013-03-14 2015-09-10 Abbvie Inc. Pyrrolopyrimindine CDK9 kinase inhibitors
AU2014231567A1 (en) 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
PT3030227T (en) 2013-08-07 2020-06-25 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2016340167B2 (en) 2015-10-16 2021-06-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
TW201840318A (en) 2017-03-09 2018-11-16 美商艾伯維有限公司 Methods of treating Crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
AR114810A1 (en) 2018-01-30 2020-10-21 Incyte Corp PROCESSES AND INTERMEDIATES TO DEVELOP A JAK INHIBITOR
MX2022012285A (en) 2018-03-30 2023-08-15 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors.
EA202190952A1 (en) 2018-10-05 2021-12-22 Аннапурна Байо, Инк. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140317A (en) * 1996-01-23 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
IL129825A0 (en) * 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
ID26698A (en) * 1998-06-19 2001-02-01 Pfizer Prod Inc PIROLO COMPOUNDS [2,3-d] PYRIMIDINE
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
KR20010085822A (en) * 1998-09-18 2001-09-07 스타르크, 카르크 4-aminopyrrolopyrimidines as kinase inhibitors
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives

Also Published As

Publication number Publication date
JP4344607B2 (en) 2009-10-14
ECSP034922A (en) 2004-04-28
EP1404676A1 (en) 2004-04-07
JP2005508300A (en) 2005-03-31
CN1294135C (en) 2007-01-10
HUP0400300A2 (en) 2007-08-28
EA007415B1 (en) 2006-10-27
EE200400003A (en) 2004-02-16
SK15882003A3 (en) 2004-07-07
WO2003000695A1 (en) 2003-01-03
OA12632A (en) 2006-06-14
CZ20033443A3 (en) 2004-03-17
HUP0400300A3 (en) 2010-12-28
GB0115393D0 (en) 2001-08-15
EE05432B1 (en) 2011-06-15
BR0210652A (en) 2004-08-10
AU2002314325B8 (en) 2009-01-29
UA76760C2 (en) 2006-09-15
CA2451932C (en) 2009-12-29
AU2002314325B2 (en) 2009-01-08
NZ529766A (en) 2008-11-28
PL374096A1 (en) 2005-09-19
TR200302242T2 (en) 2004-12-21
EA200400073A1 (en) 2004-08-26
RS99203A (en) 2006-12-15
MEP19308A (en) 2010-06-10
TNSN03144A1 (en) 2005-12-23
WO2003000695A8 (en) 2004-03-11
CA2451932A1 (en) 2003-01-03
CN1518552A (en) 2004-08-04

Similar Documents

Publication Publication Date Title
RS51698B (en) Pyrrolopyrimidines as protein kinase inhibitors
HRP20020547B1 (en) Azaindoles
AR036106A1 (en) SELECTIVE QUINASA INHIBITING AZAINDOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
BRPI0418082B8 (en) thiazole derivatives useful as adenosine a2a receptor antagonists
DK1020439T3 (en) Inhibitors of CETP activity
BRPI0509307A (en) alpha aryl or heteroaryl methyl beta piperidine propanamide compounds as orl1 receptor antagonists
ME00590A (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
DE60017711D1 (en) ANALOGUE OF NUCLEOSIDES AND OLIGONUCLEOTIDES
DK0402644T3 (en) N- (Aryloxyalkyl) heteroaryl piperidines and heteroaryl piperazines, process for their preparation and their use as medicaments
BR0307409A (en) 2-Furanecarboxylic acid hydrazide compounds, pharmaceutical compositions containing them and use thereof for the preparation of a preventive or therapeutic agent
HRP20020109B1 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
BR0313297A (en) 6-alkoxy pyrido pyrimidines as p-38 map kinase inhibitors
CO5580747A2 (en) N-ADAMANTILMETILO DERIVATIVES AND INTERMEDIARIES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION
CO5540313A2 (en) PIRROLOPIRIMIDINAS AS INHIBITORS OF PROTEIN QUINASA
AR038404A1 (en) USEFUL NICOTINAMIDE DERIVATIVES AS PDE4 INHIBITORS, PROCEDURE FOR THE PREPARATION OF THE COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
BR0309558A (en) Quinazoline derivatives and medicines
EA200100090A2 (en) New piperide-4-sulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them
EP1295878A4 (en) Novel pyrazinone derivatives
AR046753A1 (en) BENZOXAZINE DERIVATIVES AND USES OF THE SAME
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
BRPI0414460A (en) carboxamide derivatives of the amide type, pharmaceutical composition and their use
AR011571A1 (en) A DERIVATIVE OF NAFTALENE, ITS USE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND A PROCEDURE FOR ITS PREPARATION
RU2004130284A (en) ANTI-PARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES)
RS51518B (en) New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them